Abbosynagis is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease: • Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.• Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months.• Children less than 2 years of age and with haemodynamically significant congenital heart disease.